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Response to ‘Re. Beneﬁts of Remote Ischemic
Preconditioning in Vascular Surgery’
The authors make a good point: discrepancy between ani-
mal and clinical data is multifactorial, and the factors they
cite are likely to be an inﬂuence.
Themost recent, properly powered randomised controlled
trial (RCT) of remote ischaemic preconditioning (RIPC) in
cardiac surgery avoided the use of volatile anaesthetic agents
to avoid pharmacological preconditioning.1 This trial showed
no difference between the RIPC and no RIPC groups.
Conversely, the large RIPCON (Remote Ischemic Pre-
Conditioning) trial of RIPC in cardiac surgery is currently
recruiting using volatile agents to avoid remifentanyl,2 which
is also associated with pharmacological preconditioning.3
This highlights one of the problems with medications and
RIPC: it might be impossible to avoid those that effect RIPC
completely, but trials can adjust for the least powerful.
Additionally, patients might fare worse with the pre-
conditioning effect of RIPC than they would have done with
the preconditioning effect of the medication being withheld.
Another problem is that the mechanisms of interference are
still poorly understood, and it is likely that additional,
commonly prescribed medicines have an effect on RIPC.3,4
Other factors such as diabetes are common in vascular pa-
tients should be corrected for if trials are properly powered.
Protocols for other trials currently or about to recruit are
heterogeneous in their approach to correcting for these
factors. To date, 102 trials of remote ischaemic pre-
conditioning are registered on ClinicalTrials.gov. It is
imperative that trialists recognise and attempt to correct for
these factors as early as possible. Without this, we risk
publishing large, ﬂawed trials that essentially destroy all
interest in RIPC without a rigorous method.
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Thrombolysis in Carotid-Related Stroke Patients: What
About Plaque Hemorrhage and Disruption?
The routine practice of thrombolysis in ischemic stroke pa-
tients is derived from well-conducted, randomized controlled
trials (RCTs),1 which are the foundation of evidence-based
medicine (EBM). Those studies have proved themselves
extremely useful for stroke patients, helping somanypeople to
have better outcomes after their strokes. Currently, intrave-
nous thrombolytic therapy is recommended within 4.5 hours
of the onset of symptoms in patients with acute ischemic
stroke, once intracranial bleeding has been excluded by
computed tomography.2,3 The exact identiﬁcation of the site
of occlusion causing the ischemia or, more in general, of the
exact cause of stroke, is not considered mandatory before
starting ﬁbrinolytic therapy, as none of the RCTs studying the
effect of rt-PA in ischemic stroke patients was designed to
address the differential effects on different types or causes of
ischemic strokes by using vascular imaging.4,5 Hence, a carotid
axis scan is not routinely performed until the rt-PA adminis-
tration has been completed. Unfortunately, it is likely that not
all the patients receiving intravenous systemic rt-PA will gain
the greatest efﬁcacy and beneﬁt from ﬁbrinolytic therapy, and
this is probably related to the lack of a careful diagnosis of the
stroke etiology.6 In their capacity as stroke-treating physicians,
vascular surgeons sometimes ﬁnd themselves in the awkward
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